Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (61)	12/1/1999 9:19:00 PM
From: Marty	Read Replies (1) \| Respond to of 204

Thanks for the links, Tuck. After looking them over, I think I found a soul mate. You read the same kind of stuff I do, which is pretty hard for non-scientists, and you share my bewilderment that everyone else doesn't drop whatever else they are doing and check this out. It LOOKS like they have an extremely promising treatment approach for Alzheimer's. NEOT has developed a small molecule drug that gets through the blood brain barrier, goes specifically to the target site and nowhere else, does what it is supposed to, that is stimulates nerve growth factors, and improves memories of humans with AD by a statistically significant amount! It's safe, fast acting, and long lasting. It requires only low dosage, it's good for once a day delivery, and the patient's memory continues to improve as treatment continues, besides. There are 800 patients being tested in dozens of locations worldwide right now! And the stock is only 12 and change. Maybe everyone thinks it is still a year away and thinks, "I'll wait until 11 and a half months go by and then I'll buy some stock in this company." I see you are impatient with GLFD over the pace of their development. How come Amgen didn't put this on GLFD's front burner? This is a billion dollar a year market! What could have been more promising to them? Why aren't these developments the lead article in the New England Journal of Medicine or the Biotechs' Almanac or whatever? What is so obvious to everybody else that you and I can't see? Marty